BrainStorm Cell Therapeutics Inc.: NurOwn® autologous cell therapy platform for neurodegenerative diseases. Lead candidate for ALS, Ph2 evaluated 60 ALS pts w favorable safety/tolerability. Ph3 currently enrolling 200 pts across 6 US centers; top-line data expected in mid-2020. Phase 2 trial in progressive MS ongoing at Cleveland Clinic and Stanford University - topline data mid-2020.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Israel
Clinical Stage
Phase III
Disease Space
Central Nervous System, Rare Disease
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
<100MM
Therapeutic Modalities
Cell Therapy
Website:
Address:
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.